DoMore Diagnostics develops AI-powered digital pathology biomarkers to improve prognosis and personalize cancer treatment. Built on research from institutions including Oslo University Hospital, Oxford University and University College London, the company applies machine learning to histopathology images to help clinicians predict patient outcomes, reduce over- and undertreatment, and lower healthcare costs.

The company was founded to translate novel methods in precision medicine into clinical practice. DoMore Diagnostics’ core product offerings focus on digital pathology and outcome prediction for oncology, backed by academic collaborations and peer-reviewed research (including work published in The Lancet) and supported by grants such as the EIC Accelerator.

DoMore Diagnostics is headquartered in Oslo, Norway, and maintains partnerships with clinical and commercial collaborators while engaging investors to scale its diagnostics platform.